Pacira remains positive on the prospects for EXPAREL®, with the FDA challenges firmly behind it and 2015 sales slightly ahead of our expectations. We remain bullish on EXPAREL®’s long term growth potential with launches for oral and veterinary surgery anticipated later in 2016 as well as Pacira working on additional indications, including nerve block and chronic pain. We continue to expect Skyepharma to receive an $8m milestone from Pacira in 2016 for net sales reaching $250m over four consecuti ....
